The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer
- PMID: 12890838
- DOI: 10.1056/NEJMp030061
The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer
Comment on
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.N Engl J Med. 2003 Jul 31;349(5):427-34. doi: 10.1056/NEJMoa021491. N Engl J Med. 2003. PMID: 12890841 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical